CanSino Biologics Narrows Loss in Q1

MT Newswires Live

Apr 30, 2025

CanSino Biologics (HKG:6185, SHA:688185) narrowed its attributable loss in the first quarter to 11.5 million yuan from 170.1 million yuan in the year-ago period, a Tuesday Hong Kong bourse filing said.

Loss per share stood at 0.05 yuan, down from 0.69 yuan in the same period of the last fiscal year.

The vaccine manufacturer saw its operating revenue for the three months rise by 20% to 137.2 million yuan from 114.3 million yuan a year prior.

The firm attributed the lower loss mainly to an increase in operating revenue amid a rising market share of its vaccine product Menhycia in China, a rise in other income due to government grants and international funding support, and reduced spillover costs.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2531037204"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2531037204\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2531037204?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-30 20:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2531037204","market":"hk","top_or_hot":-1,"title":"CanSino Biologics Narrows Loss in Q1","media":"MT Newswires Live","content":"<html><body><p> CanSino Biologics (HKG:6185, SHA:688185) narrowed its attributable loss in the first quarter to 11.5 million yuan from 170.1 million yuan in the year-ago period, a Tuesday Hong Kong bourse filing said.</p><p>Loss per share stood at 0.05 yuan, down from 0.69 yuan in the same period of the last fiscal year.</p><p>The vaccine manufacturer saw its operating revenue for the three months rise by 20% to 137.2 million yuan from 114.3 million yuan a year prior.</p><p>The firm attributed the lower loss mainly to an increase in operating revenue amid a rising market share of its vaccine product Menhycia in China, a rise in other income due to government grants and international funding support, and reduced spillover costs.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CanSino Biologics Narrows Loss in Q1</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCanSino Biologics Narrows Loss in Q1\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-04-30 20:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> CanSino Biologics (HKG:6185, SHA:688185) narrowed its attributable loss in the first quarter to 11.5 million yuan from 170.1 million yuan in the year-ago period, a Tuesday Hong Kong bourse filing said.</p><p>Loss per share stood at 0.05 yuan, down from 0.69 yuan in the same period of the last fiscal year.</p><p>The vaccine manufacturer saw its operating revenue for the three months rise by 20% to 137.2 million yuan from 114.3 million yuan a year prior.</p><p>The firm attributed the lower loss mainly to an increase in operating revenue amid a rising market share of its vaccine product Menhycia in China, a rise in other income due to government grants and international funding support, and reduced spillover costs.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1574","symbol_name":"生物医药B类股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2531037204","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2531037204","pubTimestamp":1746017675,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"CanSino Biologics  narrowed its attributable loss in the first quarter to 11.5 million yuan from 170.1 million yuan in the year-ago period, a Tuesday Hong Kong bourse filing said.Loss per share stood at 0.05 yuan, down from 0.69 yuan in the same period of the last fiscal year.The vaccine manufacturer saw its operating revenue for the three months rise by 20% to 137.2 million yuan from 114.3 million yuan a year prior.The firm attributed the lower loss mainly to an increase in operating revenue amid a rising market share of its vaccine product Menhycia in China, a rise in other income due to government grants and international funding support, and reduced spillover costs.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688185":"康希诺","BK1574":"生物医药B类股","06185":"康希诺生物","BK1191":"制药","BK0239":"医药制造","BK1515":"抗疫概念","BK1161":"生物科技"},"translate_title":"康希诺生物第一季度亏损收窄","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688185":0.9,"06185":0.9},"content_text":"CanSino Biologics (HKG:6185, SHA:688185) narrowed its attributable loss in the first quarter to 11.5 million yuan from 170.1 million yuan in the year-ago period, a Tuesday Hong Kong bourse filing said.Loss per share stood at 0.05 yuan, down from 0.69 yuan in the same period of the last fiscal year.The vaccine manufacturer saw its operating revenue for the three months rise by 20% to 137.2 million yuan from 114.3 million yuan a year prior.The firm attributed the lower loss mainly to an increase in operating revenue amid a rising market share of its vaccine product Menhycia in China, a rise in other income due to government grants and international funding support, and reduced spillover costs.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}